Cargando…
A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer
Immune checkpoint inhibitors have made significant progress in the treatment of various cancers. However, due to the low ICI responsive rate for the gynecologic cancer, ICI two-drug combination therapy tends to be a predominant way for clinical treatment. Antibody-drug conjugates, a promising therap...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813853/ https://www.ncbi.nlm.nih.gov/pubmed/36618922 http://dx.doi.org/10.3389/fphar.2022.1093666 |